Pharmaceutical Business Review - Dr. C. Warren Olanow: “Pharma Two B Commences Phase IIb Study of P2B001 for Parkinson’s Disease”

New Framework for Characterizing Traumatic Brain Injury To Reveal More Detail About Patient’s Condition and Potential for Recovery

Mount Sinai Researchers Uncover a Promising New Way to Modulate Brain Cell Activity to Potentially Treat Major Depressive Disorder in Adults

Academy Award-Nominated Movie Helps Researchers Identify Brain Region Biased Towards Drug Cues and Treatment Effects in Individuals With Heroin Use Disorder

Discovery of Dopamine Receptors in a Previously Overlooked Part of the Brain Sheds Light on the Complex Circuitry for Anxiety and Depression

Mechanism by Which the Brain Weighs Positive vs. Negative Social Experience Is Revealed

Landmark Study Identifies New Genetic Cause of Neurodevelopmental Disorders, Bringing Long-Awaited Answers to Families

Mount Sinai Is First in the Nation to Perform Deep Brain Stimulation Implant as Part of Clinical Trial for Depression

New Lipid Nanoparticle Platform Delivers mRNA to the Brain Through the Blood-Brain Barrier

New Research Reveals That Meditation Induces Changes in Deep Brain Areas Associated with Memory and Emotional Regulation

Mount Sinai-Led Team Enhances Automated Method to Detect Common Sleep Disorder Affecting Millions

Researchers Unravel a Novel Mechanism Regulating Gene Expression in the Brain That Could Guide Solutions to Circadian and Other Disorders